RecruitingPhase 2NCT07610395

Trial Comparing the Safety and Efficacy of Two Different Oral VPV Doses With Placebo as Treatment for RV in Participants With COPD

A Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial Comparing the Safety and Efficacy of Two Different Oral Vapendavir (VPV) Doses With Placebo as Treatment for Rhinovirus (RV) in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Sponsor

Altesa Biosciences, Inc.

Enrollment

180 participants

Start Date

May 1, 2026

Study Type

INTERVENTIONAL

Conditions

Rhinovirus Infection

Summary

Compare the safety and efficacy of two different oral vapendavir doses with placebo in order to determine the appropriate dose of vapendavir to reduce the severity and/or duration of respiratory symptoms associated with RV infections in patients with COPD.

Eligibility

Min Age: 40 YearsMax Age: 85 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Placebo, a drug called VPV 1000 mg, and others for people with rhinovirus infection. The study is currently recruiting participants at 14 locations. People eligible for this study include aged 40 Years to 85 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGVPV 1000 mg

Vapendavir 1000 mg

DRUGVPV 500 mg

Vapendavir 500 mg

OTHERPlacebo

Placebo

Locations(14)

AMR Clinical - Tempe

Tempe, Arizona, United States

NewportNativeMD, Inc.

Newport Beach, California, United States

Apex Clinical Research

San Diego, California, United States

VM Clintrials

Miami Lakes, Florida, United States

Accelerated Clinical Trials, LLC

Snellville, Georgia, United States

Velocity Clinical Research - Valparaiso

Valparaiso, Indiana, United States

Patient First Clinical Trials (PFCTRIALS)

Lutherville, Maryland, United States

Brooklyn Clinical Research

Brooklyn, New York, United States

CRC Kings Mountain

Kings Mountain, North Carolina, United States

Remington-Davis, Inc.

Columbus, Ohio, United States

Clinical Research Associates of Central PA, LLC

DuBois, Pennsylvania, United States

Preferred Primary Care Physicians - St. Clair

Pittsburgh, Pennsylvania, United States

Velocity Clinical Research - Anderson

Anderson, South Carolina, United States

Clinical Research of Rock Hill

Rock Hill, South Carolina, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07610395

Related Trials

Using Multiomics to Define Mechanisms of Rhinovirus-induced Chronic Obstructive Pulmonary Disease Exacerbations to Develop Novel Therapies and Therapeutic Targets

NCT071122351 location

A Rhinovirus Challenge Study to Investigate Exacerbations and Immune Responses in Bronchiectasis

NCT069310021 location